1 |
Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 2023;226:109422. [PMID: 36646310 DOI: 10.1016/j.neuropharm.2023.109422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Glatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH. Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice. ACS Pharmacol Transl Sci 2023. [DOI: 10.1021/acsptsci.2c00222] [Reference Citation Analysis]
|
3 |
Awuchi CG, Aja MP, Mitaki NB, Morya S, Amagwula IO, Echeta CK, Igwe VS. New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions. Journal of Chemistry 2023;2023:1-36. [DOI: 10.1155/2023/5852315] [Reference Citation Analysis]
|
4 |
Glatfelter GC, Pham DNK, Walther D, Golen JA, Chadeayne AR, Baumann MH, Manke DR. Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines. ACS Omega. [DOI: 10.1021/acsomega.2c03476] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
5 |
Kolaczynska KE, Ducret P, Trachsel D, Hoener MC, Liechti ME, Luethi D. Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA. Eur Neuropsychopharmacol 2022;59:9-22. [PMID: 35378384 DOI: 10.1016/j.euroneuro.2022.03.006] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|